drugset / Trial / NCT02867280
Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This prospective multicenter non-randomized controlled study evaluates the efficacy and safety of treatment with Sorafenib (Nevaxar) in patients with hepatocellular carcinoma with microvascular invasion after radical resection compared to conventional therapies.
Timeline
- Start
- 2016-06-01
- Primary completion
- 2019-08-31
- Completion
- 2020-01-31
Outcome
Outcome not reported
Stopped: “Midterm analysis showed negative results.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | 400 mg | Oral |